On November 20, 2024, biopharmaceutical company Forte Biosciences announced an oversubscribed $53 million equity financing to support the continuing clinical advancement of FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. TD Cowen acted as the lead placement agent for the financing. Guggenheim Securities provided Capital Markets Advisory services to Forte Biosciences. Chardan, Rodman & Renshaw and Brookline Capital Markets acted as co-placement managers for the financing.

Wilson Sonsini Goodrich & Rosati represented Forte Biosciences in the transaction. The Wilson Sonsini team includes:

Corporate
Dan Koeppen
Ben Capps
Brandon Shaw
Dante Matera

Intellectual Property
Mike Hostetler
Minyoung Shin

For more information, please see Forte Biosciences's press release.